Abstract:Abstract Recent next-generation sequencing experiments have brought success in identifying cancer genes that were highly frequently mutated in tumors. As genomic sequencing experiments continue to identify large numbers of novel cancer mutations, one big challenge will be distinguishing driver mutations from passenger mutations. Driver mutations are the ones that have a role in oncogenesis or in the cancer phenotype, whereas passenger mutations are co-traveler that accumulate through DNA replication but are irrelevant to tumor development. From statistical point of view, driver genes are defined as those for which the non-silent mutation rate is significantly greater than a background (or passenger) mutation rate estimated from silent mutations. Statistical methods are now actively being developed to attempt to assess functional significance of a mutated gene in cancer sequencing studies. However, embedding biological knowledge on mutational process in tumors into statistical models is not trivial. These biological considerations include length of protein coding regions, gene structure, transcript isoforms, difference in mutation types, variation in background mutation rates, redundancy of the genetic code, multiple mutations in one gene, and functional consequence of different tumor types. They have not yet been fully addressed by current methods and tools for identifying driver genes. Driver mutations could be either common or rare among tumors. Identification of rare driver mutations may pose a potential challenge. In addition, mutation in one member of a collection of functionally related genes may result in the same net effect, and/or mutations in certain genes may be observed less frequently if they play functional roles in later stages of tumor development. At the pathway level, the frequency of rare driver mutations is accumulated in that pathway which warrants sufficient detection power. Thus, there is an increasing interest in the identification of driver pathways in tumor formation and progression. To meet these challenges, we developed a tool-DrGaP for identify driver genes and pathways in cancer sequencing studies. We introduced the Poisson processes to model the random nature of somatic mutation under no selection pressure. The new model can handle the identification of both driver genes and pathways or any gene sets in the same statistical framework. The new tool provides several significant improvements and increased power over current existing methods through simulations. To illustrate its utility, we applied the DrGaP to analysis of a recent lung cancer sequencing study. The DrGaP identified a few novel driver genes that were missed by previous methods, demonstrating its high accuracy and sensitivity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3971. doi:1538-7445.AM2012-3971

Mutation-Profile-Based Methods for Understanding Selection Forces in Cancer Somatic Mutations: A Comparative Analysis

Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Abstract 3971: DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies

Remarkable Difference of Somatic Mutation Patterns Between Oncogenes and Tumor Suppressor Genes.

Analytical Methods for Inferring Functional Effects of Single Base Pair Substitutions in Human Cancers

A Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer Types

An Evolutionary Perspective On Single-Nucleotide Polymorphism Screening In Molecular Cancer Epidemiology

Hierarchical Bayesian analysis of somatic mutation data in cancer

Assessment of Computational Methods for Predicting the Effects of Missense Mutations in Human Cancers.

Defining relative mutational difficulty to understand cancer formation

A new era of mutation rate analyses: Concepts and methods

Identification and Analysis of Sex-Biased Copy Number Alterations

CanDriS: posterior profiling of cancer-driving sites based on two-component evolutionary model

Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects

Network-Based Coverage of Mutational Profiles Reveals Cancer Genes

Mutational Processes Molding the Genomes of 21 Breast Cancers

WeSME: uncovering mutual exclusivity of cancer drivers and beyond

A tug-of-war between driver and passenger mutations in cancer and other adaptive processes

Characterization of Potential Driver Mutations Involved in Human Breast Cancer by Computational Approaches

e-MutPath: computational modeling reveals the functional landscape of genetic mutations rewiring interactome networks

Propagation of weakly advantageous mutations in cancer cell population